How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
13
HBIO Quote, Financials, Valuation and Earnings
Last price:
$0.50
Seasonality move
:
3.54%
Day range:
$0.48 - $0.53
52-week range:
$0.28 - $1.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.25x
P/B ratio:
1.59x
Volume:
688.1K
Avg. volume:
399.3K
1-year change:
-71.7%
Market cap:
$22.3M
Revenue:
$94.1M
EPS (TTM):
-$1.22
Analysts' Opinion
-
Consensus RatingHarvard Bioscience, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.00, Harvard Bioscience, Inc. has an estimated upside of 299.28% from its current price of $0.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.50.
Fair Value
-
According to the consensus of 2 analysts, Harvard Bioscience, Inc. has 299.28% upside to fair value with a price target of $2.00 per share.
HBIO vs. S&P 500
-
Over the past 5 trading days, Harvard Bioscience, Inc. has underperformed the S&P 500 by -15.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Harvard Bioscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harvard Bioscience, Inc. revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Harvard Bioscience, Inc. reported revenues of $20.6M.
Earnings Growth
-
Harvard Bioscience, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Harvard Bioscience, Inc. reported earnings per share of -$0.03.
Enterprise value:
58.3M
EV / Invested capital:
--
Price / LTM sales:
0.25x
EV / EBIT:
--
EV / Revenue:
0.67x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
9.51x
Price / Operating cash flow:
3.62x
Enterprise value / EBITDA:
12.49x
Gross Profit (TTM):
$45.3M
Return On Assets:
-54.29%
Net Income Margin (TTM):
-61.62%
Return On Equity:
-155.33%
Return On Invested Capital:
-68.29%
Operating Margin:
1.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $112.5M | $97.7M | $87.4M | $22M | $20.6M | |
| Gross Profit | $60M | $51.7M | $45.3M | $11.4M | $11.2M | |
| Operating Income | $1.6M | -$4.5M | -$1.6M | -$1.7M | $245K | |
| EBITDA | $8.8M | $2.5M | $4.7M | $76K | $1.6M | |
| Diluted EPS | -$0.08 | -$0.33 | -$1.22 | -$0.11 | -$0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $55.7M | $51.8M | $50.5M | $46.8M | $43.8M | |
| Total Assets | $153.9M | $147M | $139.7M | $131.2M | $78M | |
| Current Liabilities | $23.5M | $21.4M | $24.2M | $22.8M | $54.4M | |
| Total Liabilities | $77M | $75M | $65.4M | $65.9M | $63.9M | |
| Total Equity | $76.9M | $72M | $74.3M | $65.3M | $14.1M | |
| Total Debt | $54.1M | $54.8M | $43.2M | $44.6M | $41.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.4M | $4M | $7.9M | -$842K | $830K | |
| Cash From Investing | -$973K | -$1.9M | -$1.7M | -$1.1M | -$348K | |
| Cash From Financing | -$10.7M | -$2.9M | -$4.4M | $2.1M | -$1M | |
| Free Cash Flow | $10.9M | $160K | $6.1M | -$2M | $482K | |
HBIO
Sector
Market Cap
$22.3M
$24.3M
Price % of 52-Week High
27.83%
50%
Dividend Yield
0%
0%
Shareholder Yield
-2.42%
-1.67%
1-Year Price Total Return
-71.7%
-21.43%
Beta (5-Year)
1.526
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.57
200-day SMA
Sell
Level
$0.51
Bollinger Bands (100)
Sell
Level
0.45 - 0.69
Chaikin Money Flow
Sell
Level
-509.6K
20-day SMA
Sell
Level
$0.61
Relative Strength Index (RSI14)
Sell
Level
30.36
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-89.4323
50-day SMA
Sell
Level
$0.67
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-1.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.334)
Buy
CA Score
(Annual)
Level (-0.2642)
Buy
Beneish M-Score
(Annual)
Level (-3.07)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.6816)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
Stock Forecast FAQ
In the current month, HBIO has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The HBIO average analyst price target in the past 3 months is $2.00.
-
Where Will Harvard Bioscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harvard Bioscience, Inc. share price will rise to $2.00 per share over the next 12 months.
-
What Do Analysts Say About Harvard Bioscience, Inc.?
Analysts are divided on their view about Harvard Bioscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harvard Bioscience, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Harvard Bioscience, Inc.'s Price Target?
The price target for Harvard Bioscience, Inc. over the next 1-year time period is forecast to be $2.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is HBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harvard Bioscience, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of HBIO?
You can purchase shares of Harvard Bioscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harvard Bioscience, Inc. shares.
-
What Is The Harvard Bioscience, Inc. Share Price Today?
Harvard Bioscience, Inc. was last trading at $0.50 per share. This represents the most recent stock quote for Harvard Bioscience, Inc.. Yesterday, Harvard Bioscience, Inc. closed at $0.50 per share.
-
How To Buy Harvard Bioscience, Inc. Stock Online?
In order to purchase Harvard Bioscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HBIO
Sector
P/E ratio
--
23.33x
PEG ratio
0.00x
-0.01x
P/B ratio
1.59x
1.78x
Price / LTM sales
0.25x
1.53x
Growth Metrics
HBIO
Sector
Revenue growth
-6.28%
4%
Earnings growth
74.93%
11.06%
Revenue (5-year growth)
-4.12%
6.22%
Earnings forecast
$0.04
-$0.19
Profitability
HBIO
Sector
Profitability FY 2024
$49.6M
$3M
Return on invested capital
-68.29%
-33.25%
Return on assets
-54.29%
-29.67%
Return on equity
-155.33%
-38.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
HBIO
Sector
Total cash
$6.8M
$25M
Short term investments
--
$24.9M
Total assets
$126.6M
$72.5M
Long term debt
$41.3M
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
